Good Morning, Traders!…👋

U.S. stock futures fell sharply on Monday, as fears of escalating trade tensions ahead of President Trump's tariff announcements weighed on investor sentiment.

Markets are poised to end March on a weak note, following a turbulent month and quarter dominated by Trump's evolving tariff policies. Last week marked the fifth in six weeks that both the S&P 500 and Nasdaq Composite finished the week in the red.

Gold surged to a new record high, surpassing $3,100 for the first time, as investors flocked to safer assets amid stock market volatility. The precious metal traded at $3,147 an ounce, up more than 1%.

Markets are also closely monitoring economic indicators for signs of stress, particularly after stocks dropped in response to a higher-than-expected reading on the core PCE, the Federal Reserve’s preferred inflation measure. The March jobs report, due on Friday, will be the key data point for the week, with updates on private payrolls and job openings also set to be released.

Earnings Watch

Earnings land today from PVH $PVH ( ▲ 18.24% )  , Progress Software $PRGS ( ▲ 12.13% )  , and Nano-X Imaging $NNOX ( ▼ 3.3% )  , among others.

Analysts see PVH topping $4.15 EPS on strong apparel demand, Progress eyeing $1.25 EPS with tech growth, and Nano-X poised for a breakout

Happening Today

✓ 09:45 AM ET – Chicago PMI (Mar)

PREMARKET SNAPSHOT 📈

​U.S. stock futures are down, with the S&P 500, Dow, and NASDAQ all showing declines. ​

SECTOR SNAPSHOT✨

Friday markets was a rough day across the board as nearly all major sectors closed in the red. Consumer discretionary and communication services led the declines with steep losses, while tech, financials, and industrials also saw sharp pullbacks. Defensive areas like consumer staples and health care offered little shelter. Utilities stood out as the lone gainer, posting a modest uptick amid the broader selloff.

4o

PreMarket Unusual Volume Stocks

📈 Conduit Pharmaceuticals Inc. $CDT ( ▼ 7.54% )  is seeing notable early activity with 526.84K shares traded in the pre-market, well above its average volume of 37K, reflecting a spike of over 1,300%. The stock is up nearly 9%, signaling increasing interest—possibly ahead of company updates or sector-wide momentum.

📈 Mawson Infrastructure Group Inc. $MIGI ( ▼ 4.54% )  has recorded 599.17K shares in pre-market volume versus its 56K average, a sharp increase of nearly 1,000%. The stock is trading up more than 6%, suggesting fresh interest from crypto-related or energy-focused investors.

📈 iCoreConnect Inc. $ICCT ( ▲ 110.71% )  is making waves with a massive 29.45M shares traded pre-market, compared to its 6.5M average. Up over 133%, the surge in volume and price suggests a strong reaction to company-specific news or a breakout move.

📈 Treasure Global Inc. $TGL ( ▼ 9.09% )  is up nearly 35% with 46.65M shares exchanged versus a 22.6M average. The spike in early activity may indicate renewed attention from retail traders or a short squeeze in play.

📈 Citius Oncology, Inc. $CTOR ( ▼ 7.53% )  is trading sharply higher, up nearly 67%, with 20.76M shares in volume compared to an 13.8M average. The biotech stock is drawing strong interest, potentially fueled by catalysts in the oncology space.

Premarket Picks

Treasure Global Inc. (TGL) saw a significant surge, with its pre-market price rising to $0.13, up 61.62%. This jump came after the company filed an 8-K form with the SEC.

Reviva Pharmaceuticals Holdings, Inc. (RVPH) experienced a pre-market surge of 13.86%, bringing its price to $1.15. This increase follows Reviva's announcement that it will present topline data for the long-term OLE portion of the RECOVER study in schizophrenia at the 2025 SIRS Congress.

CERo Therapeutics Holdings, Inc. (CERO) saw a pre-market surge of 14.38%, with its price reaching $0.85. The boost comes as CERo is set to initiate enrollment for a Phase 1 trial of CER-1236 in AML, following a positive FDA review of its manufacturing process.

bluebird bio, Inc. (BLUE) rose 8.09%, with its pre-market price reaching $4.41. The increase follows the company’s confirmation of receiving an unsolicited non-binding proposal from Ayrmid.

Below is a complete list of hot stocks in pre-market today:

Top Upgrades:

1. Progyny, Inc. $PGNY ( ▲ 3.36% ) 

Analyst Firm: BTIG
Upgraded: Neutral to Buy
Price Target: $28
Friday's Close: $21.90

BTIG analyst David Larsen raised Progyny's rating to Buy from Neutral, setting a price target of $28.Progyny, Inc. offers fertility, family building, and women’s health benefits across the U.S. Analysts have set a stock price target range for the company with a high of $34.00, a median of $26.00, and a low of $23.00. The average stock price target is $26.57.

2. Steel Dynamics, Inc. $STLD ( ▼ 0.86% ) 

Analyst Firm: BMO Capital
Upgraded: Market Perform to Outperform
Price Target: $145
Friday's Close: $123.97

BMO Capital boosted Steel Dynamics' rating to Outperform from Market Perform, increasing its price target to $145, up from $135. Steel Dynamics, Inc. is a leading steel producer and metal recycler based in the U.S. Analysts estimate the stock price target for Steel Dynamics with a high of $165.00, a median of $145.00, and a low of $136.00. The average stock price target stands at $148.27.

3. Waters Corporation $WAT ( ▼ 3.41% )  

Analyst Firm: KeyBanc
Upgraded: Sector Weight to Overweight
Price Target: $460
Friday's Close: $362.16

KeyBanc upgraded Waters to Overweight from Sector Weight, with a price target of $460. Waters Corporation provides analytical workflow solutions across Asia, the Americas, and Europe. The stock price target estimates for Waters Corporation include a high of $460.00, a median of $410.00, and a low of $360.00. The average target is $412.06.

Happy investing,

Maeve Grace
Editor In Chief
Premium Stock Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.